title: C.E.R.A. administered once monthly corrects and maintains stable hemoglobin levels in chronic kidney disease patients not on dialysis: the observational study MICENAS II.
abstract: OBJECTIVE
  C.E.R.A. (continuous erythropoietin receptor activator, pegilated-rHuEPO ß) corrects and maintains stable hemoglobin levels in once-monthly administration in chronic kidney disease (CKD) patients. The aim of this study was to evaluate the management of anemia with C.E.R.A. in CKD patients not on dialysis in the clinical setting.
  
  
  METHODS
  Two hundred seventy two anemic CKD patients not on dialysis treated with C.E.R.A. were included in this retrospective, observational, multicentric study during 2010. Demographical characteristics, analytical parameters concerning anemia, treatment data and iron status were recorded.
  
  
  RESULTS
  C.E.R.A. achieved a good control of anemia in both naïve patients (mean Hemoglobin 11.6g/dL) and patients converted from a previous ESA (mean Hemoglobin 11.7g/dL). Most naïve patients received C.E.R.A. once monthly during the correction phase and required a low monthly dose (median dose 75 µg/month). The same median dose was required in patients converted from a previous ESA, and it was lower than recommended in the Summary of Product Characteristics (SPC). Iron status was adequate in 75% of anemic CKD patients, but only 50% of anemic patients with iron deficiency received iron supplementation.
  
  
  CONCLUSIONS
  C.E.R.A. corrects and maintains stable hemoglobin levels in anemic CKD patients not on dialysis, requiring conversion doses lower than those recommended by the SPC, and achieving target hemoglobin levels with once-monthly dosing frequency both in naïve and converted patients.
authors.forename: Alberto
authors.initials: A
authors.lastname: Martínez-Castelao
authors.forename: Aleix
authors.initials: A
authors.lastname: Cases
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Coll
authors.forename: Jordi
authors.initials: J
authors.lastname: Bonal
authors.forename: Josep M
authors.initials: JM
authors.lastname: Galceran
authors.forename: Joan
authors.initials: J
authors.lastname: Fort
authors.forename: Francesc
authors.initials: F
authors.lastname: Moreso
authors.forename: Vicente
authors.initials: V
authors.lastname: Torregrosa
authors.forename: Lluís
authors.initials: L
authors.lastname: Guirado
authors.forename: Pilar
authors.initials: P
authors.lastname: Ruiz
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000740:Anemia / Q000209:etiology / Q000517:prevention & control*; D018798:Anemia, Iron-Deficiency / Q000097:blood / Q000188:drug therapy / Q000209:etiology; D003928:Diabetic Nephropathies / Q000097:blood; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007501:Iron / Q000097:blood; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000097:blood* / Q000150:complications; D012189:Retrospective Studies; D055815:Young Adult
chemical_list: D006454:Hemoglobins; C508420:continuous erythropoietin receptor activator; D004921:Erythropoietin; D011092:Polyethylene Glycols; D007501:Iron